Agios Pharmaceuticals (AGIO) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to -$453.7 million.
- Agios Pharmaceuticals' Retained Earnings fell 76575.83% to -$453.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$453.7 million, marking a year-over-year decrease of 76575.83%. This contributed to the annual value of -$148.9 million for FY2024, which is 8189.7% up from last year.
- According to the latest figures from Q3 2025, Agios Pharmaceuticals' Retained Earnings is -$453.7 million, which was down 76575.83% from -$350.2 million recorded in Q2 2025.
- Agios Pharmaceuticals' 5-year Retained Earnings high stood at $30.8 million for Q1 2021, and its period low was -$1.0 billion during Q2 2024.
- Over the past 5 years, Agios Pharmaceuticals' median Retained Earnings value was -$425.3 million (recorded in 2022), while the average stood at -$422.5 million.
- As far as peak fluctuations go, Agios Pharmaceuticals' Retained Earnings soared by 10198.22% in 2021, and later crashed by 118114.75% in 2022.
- Agios Pharmaceuticals' Retained Earnings (Quarter) stood at -$238.8 million in 2021, then plummeted by 97.09% to -$470.6 million in 2022, then crashed by 74.82% to -$822.6 million in 2023, then soared by 81.9% to -$148.9 million in 2024, then plummeted by 204.63% to -$453.7 million in 2025.
- Its Retained Earnings was -$453.7 million in Q3 2025, compared to -$350.2 million in Q2 2025 and -$238.2 million in Q1 2025.